source
- Madrigal secures fourth MASH partnership, snapping up Arrowhead drug passed over by J&JMadrigal Pharmaceuticals announced its latest collaboration, marking the fourth deal focused on metabolic dysfunction-associated steatohepatitis (MASH) within a ten‑month span. The agreement bring…
- Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setbackCytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…